Vesomni

Vesomni is a fixed-dose combination tablet containing solifenacin succinate and tamsulosin hydrochloride, prescribed for men with moderate to severe storage symptoms (urgency, frequency, urge incontinence) and voiding symptoms (hesitancy, weak stream) associated with benign prostatic hyperplasia (BPH).

Tamsulosin is an alpha-1A adrenoceptor antagonist that relaxes the smooth muscle of the prostate and bladder neck, improving urinary flow and relieving obstructive symptoms.

Solifenacin is an antimuscarinic agent that reduces involuntary detrusor muscle contractions, alleviating the storage symptoms that many men with BPH experience alongside their voiding difficulties.

Combining these two mechanisms in a single tablet addresses both components of lower urinary tract symptoms.

Clinical trials (NEPTUNE and NEPTUNE II) showed that the combination provided statistically significant improvement in both storage and voiding symptom scores compared with tamsulosin alone.

Vesomni is intended for patients in whom monotherapy with an alpha-blocker has provided insufficient relief of storage symptoms.

It is not a first-line treatment but rather a step-up option when voiding symptoms are controlled but urgency, frequency, or nocturia persist.

Take one tablet daily, with or without food. Swallow the tablet whole with water; do not crush, chew, or split it, as the tamsulosin component has a modified-release coating.

Take the dose at approximately the same time each day. The tablet may be taken at any time and does not require administration after a meal, unlike some tamsulosin-only products.

Continue treatment as directed by your prescriber.

If you experience difficulty passing urine, stop the medication and seek medical advice promptly, as the antimuscarinic component can occasionally worsen urinary retention.

One tablet daily, containing solifenacin 6 mg and tamsulosin 0.4 mg (modified release). This is the only available strength and dose adjustment within the combination is not possible.

In patients with moderate renal impairment or mild to moderate hepatic impairment, no dose adjustment is needed but use with caution.

Vesomni is not recommended in severe renal impairment (GFR below 30 mL/min), severe hepatic impairment (Child-Pugh C), or with concomitant strong CYP3A4 inhibitors.

Dry mouth is the most common side effect, reported in approximately 7 to 10 per cent of patients. Constipation, dyspepsia, and nausea are also related to the solifenacin component.

Dizziness and nasal congestion are attributable to tamsulosin. Abnormal ejaculation, including reduced volume or retrograde ejaculation, occurs in a small proportion of men.

Blurred vision, dry eyes, and urinary tract infection have been reported.

Urinary retention is an important potential adverse effect, particularly in men with very large prostates or pre-existing severe bladder outflow obstruction.

Cognitive effects, including confusion and hallucinations, are a concern in elderly patients, as with all antimuscarinic agents. QT prolongation has been observed rarely at higher solifenacin doses.

Intraoperative floppy iris syndrome may occur during cataract surgery, related to the tamsulosin component.

Monitor for urinary retention, especially during the first weeks of treatment.

If you notice increasing difficulty in starting to urinate, a significantly weakened stream, or an inability to pass urine at all, stop Vesomni and seek medical help immediately.

Use with caution in patients with controlled narrow-angle glaucoma, gastrointestinal obstructive conditions, or a history of QT prolongation.

Anticholinergic burden should be assessed in elderly patients on multiple medications.

Inform your ophthalmologist of tamsulosin use before any cataract surgery. Discuss treatment with your prescriber if you have significant renal or hepatic impairment.

Vesomni is contraindicated in patients with urinary retention, severe gastrointestinal conditions such as toxic megacolon, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment, severe renal impairment, dialysis, a history of orthostatic hypotension, or hypersensitivity to any component.

It should not be co-administered with strong CYP3A4 inhibitors in patients who also have renal or hepatic impairment.